Current Value
$9.461 Year Return
Current Value
$9.461 Year Return
Double maintains 1 strategies that include NRIX - Nurix Therapeutics, Inc.
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
IBTF | 0.19% | $2.12B | 0.07% |
SCHO | -0.23% | $10.87B | 0.03% |
IBTG | -0.26% | $1.88B | 0.07% |
CGSM | 0.42% | $658.61M | 0.25% |
VGSH | 0.77% | $22.38B | 0.03% |
USFR | -0.83% | $18.91B | 0.15% |
BSMW | -0.85% | $102.62M | 0.18% |
GSST | -0.94% | $857.21M | 0.16% |
SOYB | 1.04% | $25.54M | 0.22% |
ICSH | 1.16% | $6.10B | 0.08% |
MLN | 1.18% | $532.71M | 0.24% |
FMHI | -1.19% | $757.44M | 0.7% |
UNG | 1.25% | $371.83M | 1.06% |
SHYD | 1.26% | $318.05M | 0.35% |
BWX | 1.36% | $1.41B | 0.35% |
IBTH | 1.67% | $1.53B | 0.07% |
SMMU | -1.87% | $822.53M | 0.35% |
IBMN | 1.90% | $446.12M | 0.18% |
SHYM | -2.16% | $322.93M | 0.35% |
ITM | 2.17% | $1.97B | 0.18% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
DNLI | 58.14% | $2.06B | -30.04% | 0.00% |
KYMR | 57.94% | $1.95B | -15.67% | 0.00% |
IDYA | 51.31% | $1.52B | -58.32% | 0.00% |
BEAM | 49.43% | $1.73B | -27.49% | 0.00% |
OCUL | 48.00% | $1.14B | +14.35% | 0.00% |
RVMD | 47.98% | $7.35B | +1.15% | 0.00% |
XENE | 47.32% | $2.27B | -26.70% | 0.00% |
ATXS | 46.99% | $225.17M | -57.69% | 0.00% |
CRNX | 46.90% | $2.92B | -39.88% | 0.00% |
CLDX | 46.72% | $1.33B | -49.67% | 0.00% |
STOK | 46.49% | $525.77M | -31.36% | 0.00% |
ZYME | 46.43% | $810.02M | +22.92% | 0.00% |
IMNM | 46.38% | $696.10M | -44.44% | 0.00% |
RGNX | 46.18% | $433.39M | -46.03% | 0.00% |
DAWN | 45.90% | $624.39M | -61.57% | 0.00% |
ARQT | 45.26% | $1.62B | +49.45% | 0.00% |
SYRE | 44.98% | $877.54M | -61.53% | 0.00% |
CZR | 44.75% | $6.30B | -14.16% | 0.00% |
APGE | 44.60% | $2.42B | -24.39% | 0.00% |
ACLX | 44.54% | $3.22B | +10.72% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
STG | <0.01% | $27.05M | -37.35% | 0.00% |
CL | -0.02% | $72.64B | -5.18% | 2.25% |
EDU | -0.07% | $7.99B | -41.11% | 0.00% |
VHC | 0.07% | $34.69M | +74.89% | 0.00% |
ZCMD | 0.10% | $32.45M | -11.38% | 0.00% |
FATBB | 0.14% | $50.77M | -11.65% | 9.83% |
LTM | -0.14% | $11.01B | -96.75% | 2.75% |
DADA | 0.14% | $526.11M | +11.54% | 0.00% |
MDLZ | -0.28% | $84.34B | -9.43% | 2.85% |
LRN | 0.29% | $6.69B | +118.03% | 0.00% |
MNOV | 0.32% | $68.17M | -2.80% | 0.00% |
AEP | -0.35% | $54.28B | +9.80% | 3.61% |
AWK | 0.52% | $27.37B | +4.54% | 2.22% |
RLX | -0.57% | $1.77B | -9.30% | 0.49% |
GO | 0.58% | $1.37B | -35.98% | 0.00% |
RRGB | 0.61% | $56.21M | -54.94% | 0.00% |
BEEM | 0.63% | $30.53M | -68.83% | 0.00% |
K | 0.69% | $28.49B | +32.17% | 2.77% |
EXC | -0.72% | $43.84B | +12.45% | 3.59% |
BTCT | 0.73% | $25.35M | +93.08% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
XBI | 61.01% | $4.85B | 0.35% |
IBB | 55.45% | $5.22B | 0.45% |
PTH | 55.27% | $96.56M | 0.6% |
GNOM | 55.08% | $40.65M | 0.5% |
ARKG | 55.03% | $944.78M | 0.75% |
XPH | 53.86% | $136.58M | 0.35% |
PBE | 53.78% | $214.12M | 0.58% |
CPRJ | 53.11% | $48.43M | 0.69% |
FBT | 50.24% | $994.71M | 0.56% |
IWC | 50.22% | $766.88M | 0.6% |
IWO | 49.88% | $11.36B | 0.24% |
PINK | 49.59% | $131.52M | 0.5% |
VTWO | 48.53% | $12.07B | 0.07% |
IWM | 48.43% | $63.95B | 0.19% |
KJUL | 48.18% | $113.35M | 0.79% |
ISCG | 47.42% | $645.00M | 0.06% |
SCHA | 47.07% | $16.91B | 0.04% |
BBH | 46.82% | $327.42M | 0.35% |
GSSC | 46.78% | $538.65M | 0.2% |
KJAN | 46.71% | $305.13M | 0.79% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
VIXY | -36.81% | $109.64M | 0.85% |
BTAL | -35.67% | $361.41M | 1.43% |
TAIL | -32.47% | $140.49M | 0.59% |
TPMN | -12.83% | $31.54M | 0.65% |
FXY | -11.35% | $838.61M | 0.4% |
IVOL | -11.25% | $353.94M | 1.02% |
JMST | -10.75% | $3.65B | 0.18% |
WEAT | -9.19% | $115.83M | 0.28% |
CTA | -7.96% | $1.05B | 0.76% |
ULST | -7.64% | $637.77M | 0.2% |
TFLO | -7.56% | $7.06B | 0.15% |
GBIL | -7.08% | $6.17B | 0.12% |
XHLF | -6.16% | $1.46B | 0.03% |
FTSD | -5.74% | $212.46M | 0.25% |
UDN | -5.51% | $137.74M | 0.78% |
TBLL | -5.45% | $2.46B | 0.08% |
FXE | -4.92% | $525.40M | 0.4% |
CLIP | -4.85% | $1.50B | 0.07% |
BIL | -4.62% | $45.95B | 0.1356% |
BILS | -3.65% | $3.96B | 0.1356% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CBOE | -12.68% | $22.95B | +20.67% | 1.12% |
CME | -12.41% | $98.74B | +28.80% | 3.84% |
TLPH | -9.49% | $10.05M | -57.39% | 0.00% |
CYCN | -6.67% | $9.37M | +2.39% | 0.00% |
VSA | -6.12% | $7.04M | -49.24% | 0.00% |
ED | -5.82% | $36.75B | +5.26% | 3.28% |
LITB | -5.08% | $21.28M | -72.45% | 0.00% |
MKTX | -4.97% | $8.01B | -1.42% | 1.39% |
QXO | -4.92% | $8.44B | -84.99% | 0.00% |
FMTO | -4.80% | $45.74M | -99.96% | 0.00% |
NOC | -4.43% | $67.51B | -0.35% | 1.76% |
VSTA | -4.34% | $326.82M | +11.64% | 0.00% |
NEUE | -4.15% | $62.05M | +13.56% | 0.00% |
T | -3.86% | $196.66B | +57.98% | 4.07% |
PRPO | -3.70% | $10.84M | +15.14% | 0.00% |
CARV | -3.69% | $7.41M | -22.87% | 0.00% |
AIFU | -3.24% | $9.85M | -95.03% | 0.00% |
DUK | -2.81% | $90.12B | +12.74% | 3.61% |
VZ | -2.80% | $183.32B | +8.02% | 6.21% |
PULM | -2.73% | $23.82M | +239.64% | 0.00% |
Yahoo
SAN FRANCISCO, May 16, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases, today announced that on May 13, 2025, the company granted inducement awards to thirteen new employees. The grants were made pursuant
Yahoo
SAN FRANCISCO, May 15, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that Hans van Houte, chief financial officer of Nurix, and Jason Kantor, Ph.D., chief business officer of Nurix, will participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 21, 2025, at 2:05 p.m. ET.
Yahoo
SAN FRANCISCO, May 14, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that data from the Company’s ongoing Phase 1a/b clinical trial of bexobrutideg (NX-5948) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and Waldenström macroglobulinemia will be presented at two major upcoming scientific con
Yahoo
We recently published a list of 10 Best Low Priced Biotech Stocks to Buy Now. In this article, we are going to take a look at where Nurix Therapeutics, Inc. (NASDAQ:NRIX) stands against other best low priced biotech stocks to buy now. Is Now the Time to Buy Biotech Stocks? On May 8, Michael Yee, […]
Yahoo
Nurix’s DEL-AI platform uses a first-in-class DEL Foundation Model trained on the Company’s proprietary DNA encoded library data Nurix’s DEL Foundation Model can accurately predict novel binders to therapeutically relevant targets, including many targets considered undruggable, with the potential to accelerate the discovery of novel drugs SAN FRANCISCO, April 28, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery,
Yahoo
Nurix's lead BTK degrader, bexobrutideg, demonstrates exceptional efficiency, with a single molecule degrading approximately 10,000 copies of BTK per hour BRAF degrader demonstrates broad activity across all three BRAF mutation classes Aurora A kinase degraders demonstrate potential to address both enzymatic and scaffolding functions and promote tumor regression in brain and small cell lung cancer models SAN FRANCISCO, April 25, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a